The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

ARIAD to Present at the 29th Annual J.P. Morgan Healthcare Conference

Wednesday, January 05, 2011

ARIAD to Present at the 29th Annual J.P. Morgan Healthcare Conference07:35 EST Wednesday, January 05, 2011 CAMBRIDGE, Mass. (Business Wire) -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company and its progress in key programs on Wednesday, January 12, 2011 at 10:30 a.m. (PT)/1:30 p.m. (ET). The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://investor.ariad.com. A replay of the presentation will be available on the ARIAD website approximately 24 hours after the presentation and will be archived for three weeks. About ARIAD ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need - aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck and is in Phase 3 clinical development in patients with advanced sarcomas. ARIAD's second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information about the Company, please visit http://www.ariad.com. ARIAD Pharmaceuticals, Inc.Maria E. Cantor, 617-621-2208